Sepsis & infection

Prevalence, Risk Factors, Clinical Features, and Outcome of Influenza-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Systematic Review and Meta-Analysis

ChestPublished Systematic review and meta-analysis of observational studies

Authors' conclusion

IAPA is a common complication of severe influenza and is associated with increased mortality.

Study context

Population
Critically ill patients with influenza
Participants
1,720 patients · 10 observational studies
Comparison
Influenza-associated pulmonary aspergillosis (IAPA) vs no IAPA in critically ill patients with influenza
  • IAPAn = 331
Outcome
Prevalence of IAPA
Methodological detailsrandom effects models, one-group meta-analysis, Databases: PubMed MEDLINE, CINAHL, Cochrane Library, Embase, Scopus, Cochrane Trials, ClinicalTrials.gov
  • Random effects models
  • One-group meta-analysis
  • Databases: PubMed MEDLINE, CINAHL, Cochrane Library, Embase, Scopus, Cochrane Trials, ClinicalTrials.gov

Pooled result

As reported in the abstract

IAPA prevalence

IAPA

19.2%

331

Further pooled results

Risk factors for IAPA

OR (95% CI)
Organ transplantationI2 = 45%4.8 (1.7–13.8)
Hematogenous malignancyI2 = 0%2.5 (1.5–4.1)
ImmunocompromisedI2 = 0%2.2 (1.6–3.1)
Prolonged corticosteroid use before admissionI2 = 51%2.4 (1.4–4.3)

ICU mortality

OR (95% CI)
IAPAI2 = 0%2.6 (1.8–3.8)

Clinical and imaging features

Commonly reported clinical and imaging features not particularly associated with IAPA

Safety

Morbidity with IAPA

IAPA associated with more severe disease progression, higher complication rate, longer ICU stays and more organ supports

Original publication

Prevalence, Risk Factors, Clinical Features, and Outcome of Influenza-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Systematic Review and Meta-Analysis. Chest. Published 22 September 2023. doi:10.1016/j.chest.2023.09.019

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.